(Q37984684)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

meta-analysis

0 references

title

A systematic review of the evidence of clozapine's anti-aggressive effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Geoffrey L. Dickens

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Marco M. Picchioni

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Catherine Frogley

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

20 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

The International Journal of Neuropsychopharmacology

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

1351-1371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

The pharmacological management of violence in schizophrenia: a structured review.

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

A national study of violent behavior in persons with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Sudden death in patients receiving clozapine treatment: a preliminary investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effects of classical and atypical antipsychotic drugs on isolation-induced aggression in male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Aggressive behavior against self and others among first-admission patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

The effect of clozapine on the social behaviour schedule in patients attending a forensic psychiatry day hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Psychotic symptoms and violent behaviors: probing the components of "threat/control-override" symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

The effect of state anxiety on paranoid ideation and jumping to conclusions. An experimental investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Predictors of long-term outcome of first-episode schizophrenia: A ten-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Impact of clozapine on completed suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Dysfunctional, but not functional, impulsivity is associated with a history of seriously violent behaviour and reduced orbitofrontal and hippocampal volumes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effect of clozapine on physical and verbal aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Functional characteristics of serotonin 5-HT2A and 5-HT2C receptors in the brain and the expression of the 5-HT2A and 5-HT2C receptor genes in aggressive and non-aggressive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

From gene to aggressive behavior: the role of brain serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

The growing belief that people with mental illnesses are violent: the role of the dangerousness criterion for civil commitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine and borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Characteristics of assaultive behavior among psychiatric inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Behavioral abnormality and pharmacologic response in social isolation-reared mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Nature and frequency of aggressive behaviours among long-term inpatients with schizophrenia: a 6-month report using the modified overt aggression scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

The association between violence and lifetime suicidal thoughts and behaviors in individuals treated for substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Impulsivity, aggression and suicide risk among male schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

From conduct disorder to severe mental illness: associations with aggressive behaviour, crime and victimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Suicidal risk during treatment with clozapine: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Substance abuse and schizophrenia: pharmacotherapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Visual masking in schizophrenia: overview and theoretical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine: strong antiaggressive effects with minimal motor impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Mice lacking the immediate early gene Egr3 respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Schizophrenia and violence: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Anger, aggression, and self-harm in PTSD and complex PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Psychosis as a risk factor for violence to others: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Does clozapine decrease smoking?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Neurocognitive functioning and suicidality in schizophrenia spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Does clozapine promote employability and reduce offending among mentally disordered offenders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Probabilistic learning and inference in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Clozapine treatment of adolescents with posttraumatic stress disorder and psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Violence and schizophrenia: examining the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Violent behavior in mental illness: the role of substance abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Heterogeneity of violence in schizophrenia and implications for long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Schizophrenia, substance abuse, and violent crime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Smoking and therapeutic response to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Profiles of aggression among psychiatric patients. I. Nature and prevalence.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

High Potency Neuroleptics and Violence in Schizophrenics

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Clozapine treatment of borderline patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Low-Dose Clozapine in Acute and Continuation Treatment of Severe Borderline Personality Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

Aggression against self and aggression against others in violent psychiatric patients.

1 reference

https://api.crossref.org/works/10.1017%2FS146114571100201X

7 January 2021

10.1017/S146114571100201X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339930%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference